01 / DESIGN
What was studied?
This multinational study randomized 706 adults without diabetes to cagrilintide study groups, liraglutide or placebo. The main weight endpoint was assessed at 26 weeks.
02 / FINDINGS
What did the researchers report?
Cagrilintide groups had greater average weight reduction than placebo. Gastrointestinal symptoms and administration-site reactions were among the adverse events reported.
03 / LIMITS
How should it be interpreted?
The study was designed to explore response across regimens, not lifelong outcomes. Findings for an amylin analogue do not prove that all peptides have the same effects, or that a catalog material is a clinical formulation.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.